Castellano
Electoral Census
Electronic Office
Share
X
Facebook
Linkedin
WhatsApp
E-Mail
Copy to clipboard
INEbase
Research and development
Science and technology
Statistics on Biotechnology Use
Results year 2022
National Summary
National Summary
Business Sector
Biotechnology indicators by company size.
Units:
Specified in each variable
Select values to consult
Indicator type
Values that contain
Number of companies carrying out R&D in Biotechnology
% Companies by type of biotechnology used: Genetic Code
% Companies by type of biotechnology used: Functional Units
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering
% Companies by type of biotechnology used: Bioprocesses
% Companies by type of biotechnology used: Subcellular Organisms
% Companies by type of biotechnology used: Bioinformatics
% Companies by type of biotechnology used: Nanobiotechnology
% Companies by type of biotechnology used: Other
Companies in which biotechnology activities are: Main and/or exclusive
Companies in which biotechnology activities are: A secondary business line
Companies in which biotechnology activities are: A necessary tool for production
% Companies by final application areas of biotechnology use: Human Health
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture
% Companies by final application areas of biotechnology use: Food Products
% Companies by final application areas of biotechnology use: Agriculture and Forestry
% Companies by final application areas of biotechnology use: Environment
% Companies by final application areas of biotechnology use: Industry
R&D personnel in Biotechnology (PP)
R&D personnel in Biotechnology (PP): Research personnel
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel
R&D personnel in Biotechnology (PP). Women
R&D personnel in Biotechnology (PP). Women: Research personnel
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel
R&D personnel in Biotechnology (FTE)
R&D personnel in Biotechnology (FTE): Research personnel
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel
R&D personnel in Biotechnology (FTE). Women
R&D personnel in Biotechnology (FTE). Women: Research personnel
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel
Expenditure on internal R&D in Biotechnology (thousands of euros)
1) By type of expenditure: Current expenditure
1.1) Labour expenditure of research personnel
1.2) Labour expenditure of technical and auxiliary personnel
1.3) Other current expenditure
2) By type of expenditure: Capital expenditure
2.1) Land and buildings
2.2) Equipment and tools
2.3) Acquisition of specific R&D software
2.4) Other R&D-specific IP products
1.1) By origin of funds: Own funds
1.2) By origin of funds: Funds from the Business sector
1.3) By origin of funds: Funds from the Public Administration sector
1.4) By origin of funds: Funds from the Higher Education sector
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector
1.6) By origin of funds: Funds from the rest of the world
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting
% Companies with international revenues related to biotechnology activities
% Companies representing international revenues related to biotechnology activities
% International revenues related to biotechnology activities distributed in: Revenues from the EU
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world
% International revenues related to biotechnology activities by classification: International trade in goods and services
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain
% International revenues related to biotechnology activities by classification: Subsidies from external sources
% International revenues related to biotechnology activities by classification: Other
Selected:
67
Total:
67
Size of the company
Values that contain
Less than 250 employees
250 and more employees
Total
Selected:
3
Total:
3
Choose format of the table
Size of the company
Indicator type
.
.
.
.
.
.
.
.
.
Decimals to show:
By default
0
1
Notes
1) Data referring to all companies that carry out internal R&D in Biotechnology. 2) ' .'= numeric data equal to zero not resulting from rounding 3) FTE: Full-Time Equivalence
Total:
0
series
y
0
cells
Source:National Statistics Institute